Darren Cowzer (@CowzerDarren) header
Darren Cowzer (@CowzerDarren) profile picture

Medical oncologist @Matercancer via @MSK_DeptOfMed and @UCDMedicine

Dublin, IRE
Joined November 2018
Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)Photo by Darren Cowzer (@CowzerDarren)
Now online: Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer doi.org/10.1158/1078-0432.CC…
11
20
3,727
Darren Cowzer retweeted
Zanidatamab in HER2-PositiveMetastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01 @JAMAOnc doi.org/10.1001/jamaoncol.20… 👉IHC 3+: cORR 51.6% & mOS 18.1 mo 👉IHC 2+: cORR, 5.6% & mOS 5.2 mo 🧐Stong signal of efficacy in IHC3+, IHC is key for pts selection
1
28
60
4,223
Darren Cowzer retweeted
Final day operating in OR10 in the ⁦@Matersurgery⁩ with the legend that is Gerry McEntee today. Legacy in surgery is elusive. 34 years, 70 Registrars, 70+ SHO’s, 200+ Interns… IYKYK. Mo cheol thú. Thank you Gerry, it’s been an honour.
50
64
9
818
151,161
Darren Cowzer retweeted
🧬cfDNA in biliart tract cancers @JCOPO_ASCO 📌OncoKB level 1/2 alterations in 25% of patients 📌High tissue concordance 📌May be prognostic ✅Another data reinforcing utility of ctDNA in BTCs 👉ascopubs.org/doi/10.1200/PO-… @ASCO @curecc @PrecisionBTCnet #cancer #oncology #MedX #biliary @OncoAlert @realbowtiedoc
1
19
2
45
4,594
Darren Cowzer retweeted
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in BTC @JCOPO_ASCO doi.org/10.1200/PO-25-00355 🔎297 samples, 170 pts 👉Prognostic in part... 👉useful to understand resistance MOA 🧐 cfDNA-based NGS complementary to tissue NGS @myESMO @EASLedu @ILCAnews
4
15
1,328
Darren Cowzer retweeted
This retrospective study provides a comprehensive analysis of the clinical and genomic predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma. @cowzerdarren doi.org/10.1093/oncolo/oyae1…
3
4
701
Starting at 11:30 a.m. PST: @ASCO #GI25 poster sessions! Stop by the West Hall for #pancreaticcancer and #biliarytractcancer advances by @HardingJJMD, @EileenMOReilly, @rohit_thum, @Layalmahmasani, and more! @mskcancercenter bit.ly/3WB5q7J
8
25
2,125
Darren Cowzer retweeted
Delighted to announce Goodman Fellowship opportunity in Phase 1 Oncology for medical oncology trainees in Ireland @MaterCancer. DM us here @STARTDublinPh1 if interested
10
19
1,604
It was clear to see the enormous impact of Pat Smullen's legacy at @curraghrace this Saturday. The funds raised by Pat's family, friends, and the horse racing community since 2019 have made new clinical trials and treatment options for patients with #PancreaticCancer possible.
12
21
2,262
Great to have mentors and colleagues @ImaneDika Geoff Ku from @MSK_DeptOfMed here presenting in Ireland @CancerGathering
3
25
1,576
🩸Data from @CowzerDarren, @HardingJJMD, et al. showing how NGS of #cfDNA in HCC represents an alternative to tissue-based profiling given the high tumor-plasma NGS concordance. ➡️ brnw.ch/21wE02v #gicsm
1
4
1,002
New #JITC article: Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors bit.ly/3SiwNSE @CowzerDarren @DavidFaleckMD @MLaszkowskaMD
1
4
14
2,180
👀 Check out what’s popular this week in #JCOPO: Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced #HepatocellularCarcinoma ➡️ brnw.ch/21wDi3w @CowzerDarren @HardingJJMD #cfDNA #NGS
1
7
965
Darren Cowzer retweeted
First-line regorafenib with nivo & FOLFOX in GEJ/GC in the USA: a single-arm, single-centre, phase 2 trial @TheLancetOncol doi.org/10.1016/S1470-2045(2… 👉ORR: 76%, mPFS: 13mo, mOS: nr., regardless of PD-L1 CPS status 👉Efficacy, but also toxicity... 🧐Looks promising, ph-3 planned @myESMO @OncoAlert
16
44
4,851
Great to see the team @MSKCancerCenter building on the CALGB 80803 PET-directed therapy trial with the addition of immunotherapy. Another promising development in the fight against cancer 🎉
In this Phase Ib/II trial: The addition of #durvalumab to induction FOLFOX and PET directed chemoradiation prior to surgery is safe for LA esophageal adenocarcinoma, with a high rate of pathologic response, as well as encouraging survival data. #esosm journals.lww.com/annalsofsur…
5
1
27
4,191
Proud to see this in print. Only possible with the brilliant mentorship of @HardingJJMD and support of all STGI team @MSK_DeptOfMed @YJanjigianMD @GABOUALFA @EileenMOReilly & Co @JCOPO_ASCO
Congratulations to @CowzerDarren and team @MskccCMO, @MFBerger1, @DSolit, @Gaboualfa, and @HardingJJMD! Their paper on tumor mutation profiling of circulating cell-free DNA in people with #livercancer was published today in @JCOPO_ASCO. Read it here: ascopubs.org/doi/abs/10.1200…
12
1
60
7,443
🌍 <1 hour until TONIGHT’S cross-continental #TumorBoardTuesday 🪚@KlempnerSam @CowzerDarren join to cut deep into #GastricCancer + CLAUDIN 18.2 🪵Brush off the sawdust, throw on the oil, & grab a Guinness while you check out these #CME 👇🏽See y’all soon nitter.cf/TumorBoardTues/status/…
Replying to @TumorBoardTues
#PreTest Q1️⃣ #TumorBoardTuesday Free #CME integrityce.com/TBT2023 ➡️B4 @KlempnerSam & @CowzerDarren🗣️Novel Txs & Claudin 18.2🎯💊for Gastric Ca, test your🧠with these Q’s 🤔What Tx would you offer a 56yo♂️with pMMR, HER2–, PD-L1+ (CPS = 1), CLDN18.2+ (>75%) met gastric🦀❓
5%Bemarituzumab + chemo
8%Chemo
19%Nivolumab + chemo
69%Zolbetuximab + chemo
64 votes • Final results
3
1
6
1,330